BeiGene (SHSE:688235) FCF Margin % : -61.25% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BeiGene FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. BeiGene's Free Cash Flow for the three months ended in Dec. 2023 was ¥-2,774 Mil. BeiGene's Revenue for the three months ended in Dec. 2023 was ¥4,530 Mil. Therefore, BeiGene's FCF Margin % for the quarter that ended in Dec. 2023 was -61.25%.

As of today, BeiGene's current FCF Yield % is -9.68%.

The historical rank and industry rank for BeiGene's FCF Margin % or its related term are showing as below:

SHSE:688235' s FCF Margin % Range Over the Past 10 Years
Min: -10562.15 Med: -175.54 Max: -19.29
Current: -70.53

During the past 11 years, the highest FCF Margin % of BeiGene was -19.29%. The lowest was -10562.15%. And the median was -175.54%.

SHSE:688235's FCF Margin % is ranked better than
58.01% of 1036 companies
in the Biotechnology industry
Industry Median: -147.71 vs SHSE:688235: -70.53

BeiGene FCF Margin % Historical Data

The historical data trend for BeiGene's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene FCF Margin % Chart

BeiGene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-212.25

-489.02

-137.18

-138.83

-71.32

BeiGene Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-128.45	-153.94	-69.78	-33.33	-61.25

Competitive Comparison of BeiGene's FCF Margin %

For the Biotechnology subindustry, BeiGene's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BeiGene's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeiGene's FCF Margin % distribution charts can be found below:

* The bar in red indicates where BeiGene's FCF Margin % falls into.

BeiGene FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

BeiGene's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-12521.869	/	17556.174
	=	-71.32 %

BeiGene's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-2774.318	/	4529.807
	=	-61.25 %

BeiGene FCF Margin % Related Terms

Thank you for viewing the detailed overview of BeiGene's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene (SHSE:688235) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (SHSE:688235) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BGNE:USA 06160:Hong Kong 49BA:Germany B1GN34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (SHSE:688235) Headlines

No Headlines